NYSE · Medical - Instruments & Supplies

Haemonetics Corporation (HAE) Stock

$118.28 -2.48% NYSE: HAE Healthcare

Valuation

MetricValue
Price$118.28
Market Cap$5.38B
P/E Ratio50.65
P/B Ratio5.65
P/S Ratio3.51
EPS (TTM)$3.31
52-Week High$123.32
52-Week Low$47.32
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE11.35%
ROA4.07%
ROCE11.69%
Gross Margin57.34%
Operating Margin18.15%
Net Margin7.12%
Debt/Equity1.40
Current Ratio2.95

Annual Financials (USD)

Metric20222023202420252026
Revenue$993.0M$1.2B$1.3B$1.4B$1.3B
Operating Profit$81.0M$156.0M$165.0M$222.0M$241.0M
Net Profit$43.0M$115.0M$118.0M$168.0M$97.0M
EPS$0.84$2.24$2.29$3.31$2.05
Op Margin8.1%13.3%12.6%16.3%18.1%

Balance Sheet (USD)

Metric20222023202420252026
Total Assets$1.9B$1.9B$2.2B$2.5B$2.4B
Total Liabilities$1.1B$1.1B$1.2B$1.6B$1.6B
Cash$259.0M$284.0M$179.0M$307.0M$245.0M
Borrowings$781.0M$766.0M$808.0M$1.2B$1.2B

Latest News

1 Small-Cap Stock Worth Your Attention and 2 That Underwhelm StockStory · Jul 15, 2026 HAE: Lowering target price to $78.00 Argus Research · Jul 15, 2026 Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026 PR Newswire · Jul 8, 2026 Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now? Zacks · Jul 3, 2026 3 Reasons HAE is Risky and 1 Stock to Buy Instead StockStory · Jun 30, 2026

Cash Flow (USD)

Metric20222023202420252026
Operating Cash Flow$172.0M$273.0M$182.0M$182.0M$293.0M
Investing Cash Flow$-183.0M$-254.0M$-361.0M$-201.0M$-212.0M
Financing Cash Flow$-5.0M$-91.0M$-1.0M$-337.0M$-180.0M
Net Cash Flow$67.0M$25.0M$-106.0M$128.0M$-61.0M
Free Cash Flow$76.0M$163.0M$144.0M$142.0M$260.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-1.35
EV / EBITDA21.79
FCF Yield6.14%
Quick Ratio1.91
Interest Coverage8.03
Return 1Y92.94%
Return 3Y13.92%
Return 5Y59.21%

Ownership

Insiders Held1.22%
Institutions Held109.55%
Institutions Float Held110.90%
Institutional HolderSharesReport Date
Blackrock Inc.5,619,9792026-03-31
Neuberger Berman Group, LLC3,560,9182026-03-31
AQR Capital Management, LLC3,356,5432026-03-31
Vanguard Portfolio Management LLC2,559,3162026-03-31
Vanguard Capital Management LLC2,090,3892026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BEAMBeam Therapeutics Inc. $23.47 -5.10% -29.88 $2.42B 0.00%
BHCBausch Health Companies Inc. $6.30 -0.16% -2.00 $2.36B 0.00%
CONConcentra Group Holdings Parent, Inc. $38.54 -1.56% 23.00 $4.91B 0.70%
CPRX $31.49 +0.00% 18.00 $3.85B 0.00%
ITGRInteger Holdings Corporation $126.70 -0.02% 34.27 $4.31B 0.00%

About Haemonetics Corporation

Haemonetics Corporation (HAE) stock trades at $118.28 with a market capitalization of $5.38B. The stock is valued at a price-to-earnings (P/E) ratio of 50.65, price-to-book of 5.65, price-to-sales of 3.51. Over the past 52 weeks the stock has ranged between $47.32 and $123.32, and currently trades 4.1% below its 52-week high.

On profitability, Haemonetics Corporation generates a return on equity (ROE) of 11.35%, return on capital employed of 11.69%, an operating margin of 18.15%, a net profit margin of 7.12%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1257.03 +0.43% JNJ Johnson & Johnson $255.56 +0.90% ABBV AbbVie Inc. $285.42 +0.71% UNH UnitedHealth Group Incorporated Common Stock (DE) $401.43 -1.29% MRK Merck & Company, Inc. Common Stock (new) $145.97 +0.53% NVS Novartis AG $150.62 +0.16% AZN AstraZeneca PLC $165.41 -0.76% TMO Thermo Fisher Scientific Inc $690.00 -0.93% AMGN Amgen Inc. $432.49 -0.35% GILD Gilead Sciences, Inc. $156.19 -0.75% ABT Abbott Laboratories $104.88 +0.19% NVO Novo Nordisk A/S $38.83 -0.99%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.